Bio-Rad Laboratories shares fell sharply Thursday as investors repriced the company’s large investment exposure to Sartorius AG following Sartorius’ first-quarter 2026 results release dated April 23, 2026. Because Bio-Rad carries its equity stake in Sartorius at fair value, moves in Sartorius shares can quickly translate into changes in Bio-Rad’s reported gains or losses from equity securities, amplifying day-to-day volatility in BIO.

Bio-Rad’s financial filings emphasize that its Sartorius position is large enough to meaningfully impact quarterly results independent of Bio-Rad’s underlying Life Science and Clinical Diagnostics operations. Bio-Rad has disclosed sensitivity showing that a 10% change in Sartorius quoted prices at December 31, 2025 would equate to an approximate $566.9 million gain or loss recognized in earnings, a magnitude that can overshadow operating performance in any given period.

The selloff lands one week ahead of Bio-Rad’s scheduled first-quarter 2026 earnings release and conference call on April 30, 2026. With the next report imminent, traders are also positioning for management commentary on end-market demand (especially research funding conditions affecting Life Science) and any update on how investment-market movements are flowing through reported results.